-
Mashup Score: 2China’s NMPA Approves Cadonilimab Plus Chemo With/Without Bevacizumab in Cervical Cancer - 7 day(s) ago
Cadonilimab plus chemotherapy with or without bevacizumab has received NMPA approval for first-line recurrent or metastatic cervical cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet
China’s NMPA Approves Cadonilimab Plus Chemo With/Without Bevacizumab in Cervical Cancer #oncology #cervicalcancer https://t.co/ydOZ4uAfuo